Anup Kumar Trikannad Ashwini Kumar
Assistant Professor
Faculty Researcher
COM | Internal Med Hem-Onc
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Anup Kumar Trikannad Ashwini Kumar's research focuses on hematology and oncology, with a particular emphasis on investigating rare complications and treatment outcomes in various hematologic malignancies and conditions. His work includes studying hyperhemolysis in sickle cell disease, examining the presentation and management of hypercalcemia in precursor B-cell acute lymphoblastic leukemia, and analyzing thrombotic complications associated with COVID-19.
Dr. Kumar also investigates the risks and characteristics of acute kidney injury in patients receiving chimeric antigen receptor T cells. His publications further explore the use of specific agents like teclistamab for immune thrombocytopenia in multiple myeloma patients and eculizumab for hyperhemolysis in sickle cell disease. Additionally, his research encompasses demographic analyses of survival trends in different subtypes of Hodgkin lymphoma, utilizing population-based and retrospective SEER database studies.
Metrics
- h-index: 2
- Publications: 11
- Citations: 8
Selected Publications
-
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)
-
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)
-
Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case (2024)
-
Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024)
-
Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia (2024)
Collaboration Network
Top Collaborators
- Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature
- Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature
- Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database
- Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case
- Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature
- Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database
- Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case
- Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature
- Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database
- Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case
- Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature
- Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
Similar Researchers
Based on overlapping research topics